- Home
- VIR vs DBD Comparison
VIR vs DBD Comparison
Compare VIR & DBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIR | DBD |
|---|---|---|
| Founded | 2016 | 1859 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 2.5B |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | VIR | DBD |
|---|---|---|
| Price | $8.95 | $73.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $19.63 | ★ $90.00 |
| AVG Volume (30 Days) | ★ 2.8M | 212.7K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.49 | ★ 677.27 |
| EPS | N/A | ★ 2.54 |
| Revenue | $68,556,000.00 | ★ $3,805,700,000.00 |
| Revenue This Year | N/A | $3.56 |
| Revenue Next Year | $1,049.62 | $3.25 |
| P/E Ratio | ★ N/A | $29.00 |
| Revenue Growth | N/A | ★ 1.46 |
| 52 Week Low | $4.16 | $34.88 |
| 52 Week High | $10.91 | $84.46 |
Technical Indicators
Market Signals| Indicator | VIR | DBD |
|---|---|---|
| Relative Strength Index (RSI) | 51.48 | 48.67 |
| Support Level | $8.67 | $71.24 |
| Resistance Level | $10.29 | $84.44 |
| Average True Range (ATR) | 0.45 | 2.34 |
| MACD | -0.15 | -0.04 |
| Stochastic Oscillator | 43.40 | 44.91 |
Price Performance
Historical ComparisonAbout VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
About DBD Diebold Nixdorf Incorporated
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.